Risk Factors and Pharmacological Interventions Impacting Cerebrovascular Ischemic Events in Giant Cell Arteritis: A Narrative Review

被引:0
|
作者
Siddiqui, Muhammad Osama [1 ]
Syed, Mohammad Ali [1 ]
Qureshi, Ayaan Ahmed [1 ]
Imam, Mustafa Hussain [1 ]
Motwani, Jatin [1 ]
Kumari, Verkha [1 ]
Siddiqui, Arooba [2 ]
Ul Ain, Noor [1 ]
Jaber, Mohammed Hammad [3 ]
机构
[1] Liaquat Natl Hosp & Med Coll, Karachi, Pakistan
[2] Karachi Med & Dent Coll, Karachi, Pakistan
[3] Alzaiem Alazhari Univ, Fac Med, Khartoum, Sudan
关键词
THERAPY; COMPLICATIONS; STROKE;
D O I
10.1002/iid3.70122
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
IntroductionGiant cell arteritis (GCA) is a common vasculitis predominantly affecting larger vessels, especially in individuals aged 70-79. Cerebrovascular ischemic events (CIE), such as stroke and transient ischemic attacks, are serious but rare complications of GCA, with a pooled prevalence of 4%. Some studies found that within 2 weeks of GCA diagnosis, 74% and 34% of patients experience transient or severe ischemic events, respectively.AimsOur study aims to help physicians better manage GCA patients to reduce GCA-related CIE by indicating important risk factors and pharmacological intervention to prevent GCA-related CIE, particularly in the first few days of diagnosis when the risk of CIE is highest.MethodsA comprehensive literature search was conducted using Pubmed, Google Scholar, Scopus, and other relevant medical databases. As this study was a narrative review, the literature search was done in a nonsystematic manner. Studies published from 2000 to 2024 were reviewed in a nonsystematic manner for information on incidence, pathology, risk factors, pharmacological intervention, and management of GCA-related CIE.ResultsFindings indicate that age, male gender, hypertension, and smoking significantly increase the risk of GCA-related CIE, while factors such as anemia, higher body mass index (BMI), and elevated inflammatory markers (C-reactive protein [CRP] and erythrocyte sedimentation rate [ESR]) appear to have protective effects. Symptoms of ischemia in the ophthalmic artery were identified as the strongest predictors of CIE. Pharmacological treatments, including glucocorticoids and tocilizumab, are instrumental in managing and potentially preventing CIE in GCA patients, with adjunctive therapies such as aspirin and antiplatelet agents also showing promise.ConclusionGCA-related CIE such as stroke can be very debilitating and deadly conditions, particularly when GCA is initially diagnosed. However, with early diagnosis and proper management of risk factors, GCA-related CIE can be prevented and its severity can be reduced. Ischemia in the ophthalmic artery is found to strongly predict GCA-related CIE while aspirin and antiplatelet agent during the first 3 months may prevent GCA-related CIE. Risk factors such as BMI and smoking may help in stratifying the risk of GCA-related CIE. This review underscores the importance of further studies with detailed, well-designed approaches to risk factor analysis to strengthen these associations. Identifying these risk factors is crucial for reducing morbidity and mortality, equipping physicians to better assess and mitigate the risk of CIE in GCA patients.
引用
收藏
页数:12
相关论文
共 28 条
  • [21] A Retrospective Study of Chinese Patients With Giant Cell Arteritis (GCA) Clinical Features and Factors Associated With Severe Ischemic Manifestations
    Sun, Fei
    Ma, Sha
    Zheng, Wenjie
    Tian, Xinping
    Zeng, Xiaofeng
    MEDICINE, 2016, 95 (13) : e3213
  • [22] Cerebrovascular Ischemic Events in HIV-1-Infected Patients Receiving Highly Active Antiretroviral Therapy: Incidence and Risk Factors
    Corral, Inigo
    Quereda, Carmen
    Moreno, Ana
    Perez-Elias, Maria-Jesus
    Dronda, Fernando
    Casado, Jose-Luis
    Muriel, Alfonso
    Masjuan, Jaime
    Alonso-de-Lecinana, Maria
    Moreno, Santiago
    CEREBROVASCULAR DISEASES, 2009, 27 (06) : 559 - 563
  • [23] Ischaemic manifestations in giant cell arteritis are associated with area level socio-economic deprivation, but not cardiovascular risk factors
    Mackie, Sarah L.
    Dasgupta, Bhaskar
    Hordon, Lesley
    Gough, Andrew
    Green, Michael
    Hollywood, Jane
    Dutta, Shouma
    Bejarano, Victoria
    Jarrett, Stephen
    Morgan, Ann W.
    Pease, Colin T.
    RHEUMATOLOGY, 2011, 50 (11) : 2014 - 2022
  • [24] How to taper glucocorticoids in inflammatory rheumatic diseases? A narrative review of novel evidence in rheumatoid arthritis, systemic lupus erythematosus, and giant cell arteritis
    Buttgereit, Frank
    Palmowski, Andriko
    JOINT BONE SPINE, 2022, 89 (01)
  • [25] Utilising Retinal Phenotypes to Predict Cerebrovascular Disease and Detect Related Risk Factors in Multi-Ethnic Populations: A Narrative Review
    Injety, Ranjit J.
    Shenoy, Riddhi
    Free, Robert C.
    Minhas, Jatinder S.
    Thomas, Mervyn G.
    CEREBROVASCULAR DISEASES, 2024,
  • [26] Carotid Intima-media Thickness/Diameter Ratio and Peak Systolic Velocity as Risk Factors for Neurological Severe Ischemic Events in Takayasu Arteritis
    Wang, Li
    Sun, Ying
    Dai, Xiaojuan
    Kong, Xiufang
    Ma, Lingying
    Dai, Xiaomin
    Ma, Lili
    Jiang, Lindi
    JOURNAL OF RHEUMATOLOGY, 2022, 49 (05) : 482 - 488
  • [27] Giant cell arteritis and vascular disease-risk factors and outcomes: a cohort study using UK Clinical Practice Research Datalink
    Li, Lin
    Neogi, Tuhina
    Jick, Susan
    RHEUMATOLOGY, 2017, 56 (05) : 753 - 762
  • [28] Risk of Potential Glucocorticoid-Related Adverse Events in Patients with Giant Cell Arteritis: Results from a USA-Based Electronic Health Records Database
    Best, Jennie H.
    Kong, Amanda M.
    Unizony, Sebastian
    Tran, Oth
    Michalska, Margaret
    RHEUMATOLOGY AND THERAPY, 2019, 6 (04) : 599 - 610